Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
210 hedge funds and large institutions have $2.47B invested in Clovis Oncology, Inc. in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 89 increasing their positions, 57 reducing their positions, and 42 closing their positions.
209% more call options, than puts
Call options by funds: $145M | Put options by funds: $46.7M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
56% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 57
6% less capital invested
Capital invested by funds: $2.63B → $2.47B (-$166M)
8% less funds holding
Funds holding: 229 → 210 (-19)
40% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$114M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$85.5M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$49.5M |
| 4 |
BlackRock
New York
|
+$27.4M |
| 5 |
PC
PointState Capital
New York
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$48.2M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$18.5M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.4M |
| 4 |
SC
Samlyn Capital
New York
|
-$16.3M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$15.3M |
CLVS Hedge Fund Activity: Q2 2018 in Review
210 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2018, worth a combined $2.47B — down 6.3% from $2.63B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of CLVS and 25 opened new positions — a net loss of 17 holders — while 57 trimmed existing stakes and 89 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $114M. The largest seller was Point72 Asset Management, cutting an estimated $48.2M.
- 210 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2018, down from 229 in Q1 2018.
- Funds reported $2.47B of Clovis Oncology, Inc. stock for Q2 2018, down 6.3% quarter-over-quarter.
- 25 funds opened new Clovis Oncology, Inc. positions in Q2 2018 and 42 closed out, a net change of -17 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2018 was PFM Health Sciences, an estimated $114M added.
- The largest Clovis Oncology, Inc. seller in Q2 2018 was Point72 Asset Management, an estimated $48.2M sold.
Based on aggregated 13F filings for Q2 2018.